XML 83 R72.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment Disclosures - Summary Information for the Reportable Segments (Details) $ in Thousands |  | 3 Months Ended | 9 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2020 USD ($) facility | Sep. 30, 2020 USD ($) property | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) facility property | Sep. 30, 2019 USD ($) facility | Jan. 31, 2020 property | Dec. 31, 2019 facility | Oct. 31, 2019 property | Nov. 30, 2017 property
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Deferred tax assets valuation allowance |  | $ 31,000 |  |  | $ 31,000 |  |  |  |  |
Tax benefit recognized in conjunction with internal restructuring activities |  |  |  |  | 51,000 |  |  |  |  |
Tax benefit recognized from CARES Act |  |  |  |  | 3,600 |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 597,739 |  | $ 537,971 | 1,771,329 | $ 1,465,692 |  |  |  |
Government grant income |  | 2,153 |  |  | 16,233 |  |  |  |  |
Less: Interest income |  | (4,443) |  | (2,741) | (12,361) | (6,868) |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 28,794 |  | 63,542 | 107,143 | 192,614 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 295 |  |  | 1,099 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (9,313) |  | (9,172) | (27,451) | (26,934) |  |  |  |
Operating expenses |  | (314,292) |  | (248,069) | (1,006,146) | (630,989) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (23,373) |  | (47,311) | (83,427) | (140,321) |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 3,009 |  | 2,997 | 8,939 | 8,613 |  |  |  |
Adjustments to NOI |  | (9,510) |  | (3,755) | 70,864 | (1,643) |  |  |  |
Adjusted NOI |  | 271,059 |  | 293,462 | 846,222 | 860,164 |  |  |  |
Plus: Adjustments to NOI |  | 9,510 |  | 3,755 | (70,864) | 1,643 |  |  |  |
Interest income |  | 4,443 |  | 2,741 | 12,361 | 6,868 |  |  |  |
Interest expense |  | (56,235) |  | (61,230) | (172,161) | (167,499) |  |  |  |
Depreciation and amortization |  | (173,630) |  | (171,944) | (541,394) | (469,191) |  |  |  |
General and administrative |  | (21,661) |  | (22,970) | (67,730) | (71,445) |  |  |  |
Transaction costs |  | (2,586) |  | (1,319) | (18,061) | (7,174) |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | (34,550) |  | (38,257) | (97,723) | (115,653) |  |  |  |
Gain (loss) on sales of real estate, net |  | 149 | $ 165,000 | (784) | 247,881 | 18,708 |  |  |  |
Loss on debt extinguishments |  | (17,921) |  | (35,017) | (42,912) | (36,152) |  |  |  |
Other income (expense), net |  | 7,060 |  | 693 | 237,254 | 24,834 |  |  |  |
Income tax benefit (expense)(3) |  | (24,174) |  | 6,261 | 16,216 | 11,583 |  |  |  |
Less: Government grant income |  | (2,153) |  |  | (16,233) |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | (5,716) |  | (16,231) | (24,815) | (52,293) |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 6,304 |  | 6,175 | 18,512 | 18,321 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | (19,480) |  | (7,643) | (48,545) | (10,012) |  |  |  |
Net income (loss) |  | (59,581) |  | (42,308) | 278,008 | 12,702 |  |  |  |
Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 597,739 |  | 537,971 | 1,771,329 | 1,465,692 |  |  |  |
Corporate Non-segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 0 |  |  | 0 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Adjustments to NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Adjusted NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Plus: Adjustments to NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (51,401) |  | (58,311) | (157,883) | (161,433) |  |  |  |
Depreciation and amortization |  | 0 |  | 0 | 0 | 0 |  |  |  |
General and administrative |  | (21,661) |  | (22,970) | (67,730) | (71,445) |  |  |  |
Transaction costs |  | (2,586) |  | (1,319) | (18,061) | (7,174) |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Gain (loss) on sales of real estate, net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Loss on debt extinguishments |  | (17,921) |  | (35,017) | (42,912) | (36,152) |  |  |  |
Other income (expense), net |  | 2,765 |  | (287) | 4,569 | 11,037 |  |  |  |
Income tax benefit (expense)(3) |  | (24,174) |  | 6,261 | 16,216 | 11,583 |  |  |  |
Less: Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | 0 |  | 0 | 0 | 0 |  |  |  |
Net income (loss) |  | (114,978) |  | (111,643) | $ (265,801) | $ (253,584) |  |  |  |
Senior Housing Triple-Net |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Number of facilities transitioned | facility |  |  |  |  | 9 | 39 |  |  |  |
Senior Housing Triple-Net | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 24,558 |  | 47,956 | $ 82,282 | $ 156,592 |  |  |  |
Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 0 |  |  | 0 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | 0 |  | 0 | 0 | (1) |  |  |  |
Operating expenses |  | (421) |  | (865) | (1,453) | (2,725) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Adjustments to NOI |  | 93 |  | (1,537) | (3,240) | 3,834 |  |  |  |
Adjusted NOI |  | 24,230 |  | 45,554 | 77,589 | 157,700 |  |  |  |
Plus: Adjustments to NOI |  | (93) |  | 1,537 | 3,240 | (3,834) |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (45) |  | (106) | (199) | (901) |  |  |  |
Depreciation and amortization |  | (6,694) |  | (12,773) | (21,031) | (45,138) |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | (12,097) |  | (7,430) | (17,774) | (22,914) |  |  |  |
Gain (loss) on sales of real estate, net |  | 0 |  | 0 | 164,043 | 3,557 |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 0 |  | 0 | 0 | 1 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | 0 |  | 0 | 0 | 0 |  |  |  |
Net income (loss) |  | $ 5,301 |  | 26,782 | $ 205,868 | 88,471 |  |  |  |
SHOP |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Number of deconsolidating assets |  | 19 |  |  | 19 |  |  | 19 |  |
SHOP | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | $ 149,615 |  | 212,275 | $ 475,869 | 515,457 |  |  |  |
Government grant income |  | 392 |  |  | 2,601 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 23,800 |  | 4,943 | 74,249 | 16,514 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 49 |  |  | 319 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (459) |  | (515) | (1,501) | (1,510) |  |  |  |
Operating expenses |  | (130,729) |  | (166,201) | (406,366) | (400,608) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (18,280) |  | (3,816) | (54,922) | (12,407) |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 361 |  | 388 | 1,149 | 1,058 |  |  |  |
Adjustments to NOI |  | (1,228) |  | 739 | (579) | 2,819 |  |  |  |
Adjusted NOI |  | 23,521 |  | 47,813 | 90,819 | 121,323 |  |  |  |
Plus: Adjustments to NOI |  | 1,228 |  | (739) | 579 | (2,819) |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (2,649) |  | (2,637) | (8,341) | (4,626) |  |  |  |
Depreciation and amortization |  | (24,966) |  | (58,152) | (113,591) | (134,481) |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | (24,229) |  | (24,721) | (63,672) | (77,685) |  |  |  |
Gain (loss) on sales of real estate, net |  | (2,134) |  | (734) | (1,798) | 8,844 |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 392 |  | 0 | 2,601 | 12,817 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | (392) |  |  | (2,601) |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | (5,569) |  | (1,127) | (19,646) | (4,107) |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 98 |  | 127 | 352 | 452 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | (19,432) |  | (392) | (55,360) | (1,473) |  |  |  |
Net income (loss) |  | (54,132) |  | (40,562) | (170,658) | (81,755) |  |  |  |
CCRC | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 115,031 |  | 0 | 320,737 | 0 |  |  |  |
Government grant income |  | 1,761 |  |  | 13,632 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 4,295 |  | 52,671 | 30,723 | 157,744 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 246 |  |  | 780 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Operating expenses |  | (94,992) |  | 0 | (345,722) | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (4,797) |  | (43,193) | (27,660) | (127,026) |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Adjustments to NOI |  | 1,684 |  | 5,635 | 93,263 | 13,832 |  |  |  |
Adjusted NOI |  | 23,228 |  | 15,113 | 85,753 | 44,550 |  |  |  |
Plus: Adjustments to NOI |  | (1,684) |  | (5,635) | (93,263) | (13,832) |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (1,983) |  | 0 | (5,256) | 0 |  |  |  |
Depreciation and amortization |  | (30,106) |  | 0 | (81,760) | 0 |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Gain (loss) on sales of real estate, net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 3,903 |  | 0 | 188,377 | 0 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | (1,761) |  |  | (13,632) |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | 256 |  | (9,478) | (3,843) | (30,718) |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | (322) |  | (9,194) | (1,801) | (13,858) |  |  |  |
Net income (loss) |  | (8,469) |  | (9,194) | 74,575 | (13,858) |  |  |  |
Life Science | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 148,702 |  | 118,561 | 416,081 | 320,630 |  |  |  |
Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 0 |  |  | 0 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (66) |  | (52) | (175) | (134) |  |  |  |
Operating expenses |  | (36,714) |  | (29,520) | (101,120) | (76,992) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 18 |  | 16 | 53 | 42 |  |  |  |
Adjustments to NOI |  | (8,330) |  | (7,062) | (15,389) | (17,146) |  |  |  |
Adjusted NOI |  | 103,610 |  | 81,943 | 299,450 | 226,400 |  |  |  |
Plus: Adjustments to NOI |  | 8,330 |  | 7,062 | 15,389 | 17,146 |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (57) |  | (68) | (180) | (211) |  |  |  |
Depreciation and amortization |  | (57,170) |  | (45,028) | (159,737) | (122,705) |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Gain (loss) on sales of real estate, net |  | 0 |  | (87) | 0 | 3,651 |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 48 |  | 36 | 122 | 92 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | 0 |  | 0 | 0 | 0 |  |  |  |
Net income (loss) |  | 54,761 |  | 43,858 | 155,044 | 124,373 |  |  |  |
Medical Office | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 145,153 |  | 143,639 | 431,935 | 427,761 |  |  |  |
Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 699 |  | 701 | 2,085 | 2,115 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 0 |  |  | 0 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (8,788) |  | (8,605) | (25,775) | (25,289) |  |  |  |
Operating expenses |  | (51,430) |  | (51,472) | (151,467) | (150,635) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (296) |  | (279) | (846) | (837) |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 2,630 |  | 2,593 | 7,737 | 7,513 |  |  |  |
Adjustments to NOI |  | (2,287) |  | (1,609) | (4,695) | (4,569) |  |  |  |
Adjusted NOI |  | 85,681 |  | 84,968 | 258,974 | 256,059 |  |  |  |
Plus: Adjustments to NOI |  | 2,287 |  | 1,609 | 4,695 | 4,569 |  |  |  |
Interest income |  | 0 |  | 0 | 0 | 0 |  |  |  |
Interest expense |  | (100) |  | (108) | (302) | (328) |  |  |  |
Depreciation and amortization |  | (53,688) |  | (54,152) | (161,408) | (161,350) |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | (1,208) |  | (5,729) | (6,033) | (14,677) |  |  |  |
Gain (loss) on sales of real estate, net |  | 2,283 |  | (7) | 85,676 | 2,876 |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 0 |  | 0 | 0 | 0 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | (403) |  | (422) | (1,239) | (1,278) |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 6,158 |  | 6,012 | 18,038 | 17,776 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | 198 |  | 216 | 604 | 643 |  |  |  |
Net income (loss) |  | 41,208 |  | 32,387 | 199,005 | 104,290 |  |  |  |
Other non-reportable | Operating Segment |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Total revenues |  | 14,680 |  | 15,540 | 44,425 | 45,252 |  |  |  |
Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Interest income |  | (4,443) |  | (2,741) | (12,361) | (6,868) |  |  |  |
Healthpeak's share of unconsolidated joint venture total revenues |  | 0 |  | 5,227 | 86 | 16,241 |  |  |  |
Healthpeak's share of unconsolidated joint venture government grant income |  | 0 |  |  | 0 |  |  |  |  |
Noncontrolling interests' share of consolidated joint venture total revenues |  | 0 |  | 0 | 0 | 0 |  |  |  |
Operating expenses |  | (6) |  | (11) | (18) | (29) |  |  |  |
Healthpeak's share of unconsolidated joint venture operating expenses |  | 0 |  | (23) | 1 | (51) |  |  |  |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 0 |  | 0 | 0 | 0 |  |  |  |
Adjustments to NOI |  | 558 |  | 79 | 1,504 | (413) |  |  |  |
Adjusted NOI |  | 10,789 |  | 18,071 | 33,637 | 54,132 |  |  |  |
Plus: Adjustments to NOI |  | (558) |  | (79) | (1,504) | 413 |  |  |  |
Interest income |  | 4,443 |  | 2,741 | 12,361 | 6,868 |  |  |  |
Interest expense |  | 0 |  | 0 | 0 | 0 |  |  |  |
Depreciation and amortization |  | (1,006) |  | (1,839) | (3,867) | (5,517) |  |  |  |
General and administrative |  | 0 |  | 0 | 0 | 0 |  |  |  |
Transaction costs |  | 0 |  | 0 | 0 | 0 |  |  |  |
Impairments and loan loss reserves (recoveries), net |  | 2,984 |  | (377) | (10,244) | (377) |  |  |  |
Gain (loss) on sales of real estate, net |  | 0 |  | 44 | (40) | (220) |  |  |  |
Loss on debt extinguishments |  | 0 |  | 0 | 0 | 0 |  |  |  |
Other income (expense), net |  | 0 |  | 980 | 41,707 | 980 |  |  |  |
Income tax benefit (expense)(3) |  | 0 |  | 0 | 0 | 0 |  |  |  |
Less: Government grant income |  | 0 |  |  | 0 |  |  |  |  |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | 0 |  | (5,204) | (87) | (16,190) |  |  |  |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 0 |  | 0 | 0 | 0 |  |  |  |
Equity income (loss) from unconsolidated joint ventures |  | 76 |  | 1,727 | 8,012 | 4,676 |  |  |  |
Net income (loss) |  | $ 16,728 |  | $ 16,064 | $ 79,975 | $ 44,765 |  |  |  |
Assets Leased to Others | Senior Housing Triple-Net |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Property count | property |  |  |  |  |  |  |  |  | 43 | 78
CCRC JV | Assets Leased to Others | Other non-reportable |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Property count | 15 |  |  |  |  |  | 15 |  | 15 |
Brookedale MTCA |  |  |  |  |  |  |  |  |  |
Segment Reporting Information, Revenue for Reportable Segment [Abstract] |  |  |  |  |  |  |  |  |  |
Gain (loss) on sales of real estate, net | $ 164,000 |  |  |  |  |  |  |  |  |
Brookedale MTCA | CCRC JV |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Property count | property |  |  |  |  |  |  | 15 |  |  |
Brookedale MTCA | CCRC JV | Assets Leased to Others | Other non-reportable |  |  |  |  |  |  |  |  |  |
Segment Disclosure |  |  |  |  |  |  |  |  |  |
Ownership interest acquired |  | 100.00% |  |  | 100.00% |  |  |  |  |
Property count | 13 | 13 |  |  | 13 |  | 13 |  |  |

X
- Definition Adjusted NOI is a non-GAAP supplemental financial measure used to evaluate the operating performance of real estate. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles and lease termination fees (?non cash adjustments?). Adjusted NOI is oftentimes referred to as ?cash NOI.? The Company uses adjusted NOI to make decisions about resource allocations, and to assess and compare property level performance. The Company believes that net income (loss) is the most directly comparable U.S. GAAP measure to adjusted NOI. Adjusted NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, the Company?s definition of Adjusted NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating Adjusted NOI. + References No definition available. + Details
Name: | peak_AdjustedNetOperatingIncomeFromContinuingOperations
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Effective Income Tax Rate Reconciliation, Coronavirus Aid, Relief, And Economic Security (CARES) Act, Amount + References No definition available. + Details
Name: | peak_EffectiveIncomeTaxRateReconciliationCoronavirusAidReliefAndEconomicSecurityCARESActAmount
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Government Grant Income From CARES Act + References No definition available. + Details
Name: | peak_GovernmentGrantIncomeFromCARESAct
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Impairments And Allowance For Credit Loss Reserves (Recoveries), Net + References No definition available. + Details
Name: | peak_ImpairmentsAndAllowanceForCreditLossReservesRecoveriesNet
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Interest Income, Excluded From Adjusted Government Grant Income From Continuing Operations + References No definition available. + Details
Name: | peak_InterestIncomeExcludedFromAdjustedGovernmentGrantIncomeFromContinuingOperations
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest Income, Excluded From Adjusted Net Operating Income From Continuing Operations + References No definition available. + Details
Name: | peak_InterestIncomeExcludedFromAdjustedNetOperatingIncomeFromContinuingOperations
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net Income (Loss) Joint Venture Partners, Attributable To Parent + References No definition available. + Details
Name: | peak_NetIncomeLossJointVenturePartnersAttributableToParent
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents straight-line rents, DFL accretion, amortization of market lease intangibles and lease termination fees. + References No definition available. + Details
Name: | peak_NonCashAdjustmentsToNetOperatingIncomeFromContinuingOperations
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of Facilities Transitioned to Different Segment + References No definition available. + Details
Name: | peak_NumberOfFacilitiesTransitionedToDifferentSegment
Namespace Prefix: | peak_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Real Estate Properties Deconsolidated Into New Joint Venture + References No definition available. + Details
Name: | peak_NumberOfRealEstatePropertiesDeconsolidatedIntoNewJointVenture
Namespace Prefix: | peak_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Operating Expenses From Joint Venture, Attributable To Noncontrolling Interest + References No definition available. + Details
Name: | peak_OperatingExpensesFromJointVentureAttributableToNoncontrollingInterest
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Operating Expenses From Joint Venture, Attributable To Parent Net + References No definition available. + Details
Name: | peak_OperatingExpensesFromJointVentureAttributableToParentNet
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Real Estate Revenues From Joint Venture, Attributable To Noncontrolling Interest + References No definition available. + Details
Name: | peak_RealEstateRevenuesFromJointVentureAttributableToNoncontrollingInterest
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Real Estate Revenues From Joint Venture, Attributable To Parent + References No definition available. + Details
Name: | peak_RealEstateRevenuesFromJointVentureAttributableToParent
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Real Estate Revenues From Joint Venture Government Grant Income + References No definition available. + Details
Name: | peak_RealEstateRevenuesFromJointVentureGovernmentGrantIncome
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the addback of straight-line rents, DFL accretion, amortization of market lease intangibles and lease termination fees from segment portfolio income to consolidated net income. + References No definition available. + Details
Name: | peak_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedNonCashAdjustments
Namespace Prefix: | peak_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(9)(a)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 360 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=117337411&loc=d3e23528-158515 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(7)(c)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)(d)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 360 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=117337397&loc=d3e23439-158514 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(a)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 360 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117337397&loc=d3e23415-158514 + Details
Name: | us-gaap_GainsLossesOnSalesOfInvestmentRealEstate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details
Name: | us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details
Name: | us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 + Details
Name: | us-gaap_InterestExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_InterestIncomeOperating
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after tax of income (loss) attributable to nonredeemable noncontrolling shareholder, unit holder, partner, or other equity holder of a joint venture. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.19) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_NoncontrollingInterestInNetIncomeLossJointVenturePartnersNonredeemable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of real estate properties owned as of the balance sheet date. + References No definition available. + Details
Name: | us-gaap_NumberOfRealEstateProperties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + References No definition available. + Details
Name: | us-gaap_OperatingExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (expense) related to nonoperating activities, classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_ProfitLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_SeniorHousingTripleNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_SeniorHousingOperatingPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_CCRCSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_LifescienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_MedicalOfficeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=peak_OtherNonReportingSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorPropertyClassAxis=us-gaap_AssetsLeasedToOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=peak_CcrcJvInvestmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=peak_BrookdaleMTCAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |